Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.36 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4881811 | 0.93 | ALDH1A1 (0.34) | KDM4EKMT2AHSD17B10ALDH1A1LMNA | |
| SCHEMBL4893162 | 0.93 | ALDH1A1 (0.34) | KDM4EKMT2AHSD17B10ALDH1A1LMNA | |
| SCHEMBL4891916 | 0.92 | HRH3 (0.36) | KDM4EKMT2AHSD17B10ALDH1A1LMNA | |
| SCHEMBL4893924 | 0.92 | CASP3 (0.34) | KDM4EKMT2AHSD17B10ALDH1A1LMNA | |
| SCHEMBL4883292 | 0.91 | F2 (0.36) | KDM4EPOLBKMT2AMEN1CYP2C9 | |
| SCHEMBL4893645 | 0.91 | F2 (0.36) | KDM4EPOLBKMT2AMEN1CYP2C9 | |
| SCHEMBL4885059 | 0.91 | F2 (0.36) | KDM4EPOLBKMT2AMEN1CYP2C9 | |
| SCHEMBL5330394 | 0.90 | CHRM5 (0.35) | KDM4EHSD17B10ALDH1A1LMNAHTT | |
| SCHEMBL4892814 | 0.90 | HPGD (0.34) | KDM4EKMT2AHSD17B10ALDH1A1LMNA | |
| SCHEMBL4893430 | 0.89 | F2 (0.34) | KDM4EKCNH2KMT2AHSD17B10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221063-A1 | Heterocyclic Sulfonamide Derivatives As Inhibitors Of Factor Xa | ASTRAZENECA AB (SE) | 2008-09-11 | — | — | US | claimed |
| US-20080214495-A1 | Heterocyclic Sulfonamide Derivatives as Inhibitors of Factor Xa | ASTRAZENECA AB (SE) | 2008-09-04 | — | — | US | claimed |
| US-20080200431-A1 | 6-{4-[4-(3-Chloro-1H-indole-6-sulfonyl)-3-hydroxy-piperazine-1-carbonyl]-piperidin-1-yl}-2-methyl-2H-pyridazin-3-one for example; antithrombotic and anticoagulant; synthesis; combination therapy | ASTRAZENECA AB (SE) | 2008-08-21 | — | — | US | claimed |
| WO-2007008143-A1 | HETEROCYCLIC SULFONAMIDE DERIVATIVES AS INHIBITORS OF FACTOR XA | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | WO | claimed |
| WO-2007008146-A1 | HETEROCYCLIC SULFONAMIDE DERIVATIVES AS INHIBITORS OF FACTOR XA | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | WO | claimed |
| US-20080221063-A1 | Heterocyclic Sulfonamide Derivatives As Inhibitors Of Factor Xa | ASTRAZENECA AB (SE) | 2008-09-11 | — | — | US | disclosed |
| US-20080214495-A1 | Heterocyclic Sulfonamide Derivatives as Inhibitors of Factor Xa | ASTRAZENECA AB (SE) | 2008-09-04 | — | — | US | disclosed |
| US-20080200431-A1 | 6-{4-[4-(3-Chloro-1H-indole-6-sulfonyl)-3-hydroxy-piperazine-1-carbonyl]-piperidin-1-yl}-2-methyl-2H-pyridazin-3-one for example; antithrombotic and anticoagulant; synthesis; combination therapy | ASTRAZENECA AB (SE) | 2008-08-21 | — | — | US | disclosed |
| WO-2007008142-A1 | HETEROCYCLIC SULFONAMIDE DERIVATIVES AS INHIBITORS OF FACTOR XA | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | WO | disclosed |
| WO-2007008143-A1 | HETEROCYCLIC SULFONAMIDE DERIVATIVES AS INHIBITORS OF FACTOR XA | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | WO | disclosed |
| WO-2007008146-A1 | HETEROCYCLIC SULFONAMIDE DERIVATIVES AS INHIBITORS OF FACTOR XA | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221063-A1 | Heterocyclic Sulfonamide Derivatives As Inhibitors Of Factor Xa | F12, F11, C1R | KDM4E 2209/4885KCNH2 271/4885VCAM1 2251/4885 |
| US-20080200431-A1 | 6-{4-[4-(3-Chloro-1H-indole-6-sulfonyl)-3-hydroxy-piperazine-1-carbonyl]-piperidin-1-yl}-2-methyl-2H-pyridazin-3-one for example; antithrombotic and anticoagulant; synthesis; combination therapy | CYC1, F2, CBR1 | KDM4E 2013/4885KCNH2 108/4885VCAM1 443/4885 |
| US-20080214495-A1 | Heterocyclic Sulfonamide Derivatives as Inhibitors of Factor Xa | F10, F12, F11 | KDM4E 2392/4885KCNH2 186/4885VCAM1 1837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.